Explore more topics
SEC reporting owner

Vivo Capital Surplus Fund VIII, L.P. SEC insider disclosures

Explore Vivo Capital Surplus Fund VIII, L.P.'s reporting-owner identity, issuer relationships, purchases, sales and SEC filing receipts.

As of 2026-10-12T05:54:58.330Z

Reporting owner CIK
0001628048
Issuers
7
Coverage
verified
Jump to a section

Issuer relationships

A reporting-owner CIK identifies the filer across issuer relationships and name aliases. A filer may be an individual or an organization; the filing role is the relevant evidence.

Scroll sideways to compare all columns. Select a heading to sort.

Menlo Therapeutics, Inc.0001566044MNLONoNo
Crinetics Pharmaceuticals, Inc.0001658247CRNXNoNo
Kadmon Holdings, Inc.0001557142KDMNNoNo
Aligos Therapeutics, Inc.0001799448ALGSNoNo
Bolt Biotherapeutics, Inc.0001641281BOLTNoNo
Terns Pharmaceuticals, Inc.0001831363TERNNoNo
IMPEL PHARMACEUTICALS INC0001445499IMPLNoNo

Recent SEC transactions

Code P identifies a purchase, S a sale and A an award. Awards and open-market purchases describe different events. Use the public availability date when deciding when a researcher could have known about the transaction.

Scroll sideways to compare all columns. Select a heading to sort.

No records are available for this view.

Up to 50 transactions from the recent two-year owner window.

Source evidence and strategy eligibility

The transactions below come from filings; a historical tracker separately simulates following eligible events. Joint filers can report the same transaction, and an owner can have filings at multiple companies. Public availability, amendment lineage and verified coverage determine which events a historical tracker may use.

The current directory marks this owner's filing coverage verified.